Robert Lanza, Chief Scientific Officer at ADVANCED CELL TECHNOLOGY, INC. (ACTC), sold 600,000 shares at $0.07 ($42K) on 2010-09-20, disclosed to the SEC on 2010-09-22.
Open-market sale of $42k ACTC by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.07 | 5,000 | $350 | 0.8% |
| 2 | $0.07 | 10,000 | $700 | 1.7% |
| 3 | $0.07 | 15,000 | $1K | 2.5% |
| 4 | $0.07 | 18,000 | $1K | 3.0% |
| 5 | $0.07 | 19,000 | $1K | 3.2% |
| 6 | $0.07 | 36,506 |
| $3K |
| 6.1% |
| 7 | $0.07 | 47,500 | $3K | 7.9% |
| 8 | $0.07 | 188,200 | $13K | 31.4% |
| 9 | $0.07 | 260,794 | $18K | 43.5% |
| Total | $0.07 avg | 600,000 | $42K | 100% |
| Filing → |
| ACTC | SELL | 2012-12-18 | $80K | — | Filing → |
| ACTC | SELL | 2012-08-01 | $160K | — | Filing → |
| ACTC | SELL | 2012-01-25 | $1.4M | — | Filing → |